Literature DB >> 1704064

Potential anti-AIDS agents. Synthesis and antiviral activity of naphthalenesulfonic acid derivatives against HIV-1 and HIV-2.

P Mohan1, R Singh, M Baba.   

Abstract

Certain naphthalenesulfonic acid analogues have been synthesized and evaluated for their inhibitory effects on HIV-1- and HIV-2-induced cytopathogenicity, HIV-1 giant cell formation, and HIV-1 reverse transcriptase (RT) activity. A bis(naphthalenedisulfonic acid) derivative having a biphenyl spacer emerged as the most potent and selective inhibitor of virus-induced cytopathogenicity in MT-4 cells. The ED50 values for this compound were 7.6 and 36 microM for HIV-1 and HIV-2, respectively. No toxicity to the host cells was detected at 98 microM. This compound also inhibited giant cell formation and was superseded in potency by a bis(naphthalenedisulfonic acid) derivative having a flexible decamethylene spacer. In the cell-free RT assay, a long-chain amide derivative exhibited the most inhibition of RT. All the compounds that achieved complete inhibition of virus-induced cytopathogenicity at concentrations not toxic to host cells were derivatives of 4-amino-5-hydroxy-2,7- naphthalenedisulfonic acid. These analogues represent new leads for the development of anti-HIV agents.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1704064     DOI: 10.1021/jm00105a033

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  6 in total

1.  Enzymatic kinetic studies with the non-nucleoside HIV reverse transcriptase inhibitor U-9843.

Authors:  I W Althaus; R J LeMay; A J Gonzales; M R Deibel; S K Sharma; F J Kezdy; L Resnick; M E Busso; P A Aristoff; F Reusser
Journal:  Experientia       Date:  1992-12-01

Review 2.  Antiviral therapy for human immunodeficiency virus infections.

Authors:  E De Clercq
Journal:  Clin Microbiol Rev       Date:  1995-04       Impact factor: 26.132

3.  Naphthalene sulfonate polymers with CD4-blocking and anti-human immunodeficiency virus type 1 activities.

Authors:  S Rusconi; M Moonis; D P Merrill; P V Pallai; E A Neidhardt; S K Singh; K J Willis; M S Osburne; A T Profy; J C Jenson; M S Hirsch
Journal:  Antimicrob Agents Chemother       Date:  1996-01       Impact factor: 5.191

4.  Preclinical testing of candidate topical microbicides for anti-human immunodeficiency virus type 1 activity and tissue toxicity in a human cervical explant culture.

Authors:  James E Cummins; Jeannette Guarner; Lisa Flowers; Patricia C Guenthner; Jeanine Bartlett; Timothy Morken; Lisa A Grohskopf; Lynn Paxton; Charlene S Dezzutti
Journal:  Antimicrob Agents Chemother       Date:  2007-03-12       Impact factor: 5.191

5.  In vitro comparison of topical microbicides for prevention of human immunodeficiency virus type 1 transmission.

Authors:  Charlene S Dezzutti; V Nicole James; Artur Ramos; Sharon T Sullivan; Aladin Siddig; Timothy J Bush; Lisa A Grohskopf; Lynn Paxton; Shambavi Subbarao; Clyde E Hart
Journal:  Antimicrob Agents Chemother       Date:  2004-10       Impact factor: 5.191

Review 6.  Anti-AIDS drug development: challenges and strategies.

Authors:  P Mohan
Journal:  Pharm Res       Date:  1992-06       Impact factor: 4.200

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.